Gene therapy effective in beta-thalassemia, reduces need for transfusion: NEJM

Written By :  Medha Baranwal
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2022-01-01 03:30 GMT   |   Update On 2022-01-01 03:31 GMT
Advertisement

USA: A phase III study showed betibeglogene autotemcel (beti-cel) gene therapy to be safe and effective in patients with non-β0/β0 genotype β-thalassemia.

The study, published in the New England Journal of Medicine, found that treatment with the gene therapy led to a sustained HbAT87Q level and a total hemoglobin level that was high enough to allow transfusion independence in the study population, including those younger than 12 years of age. 

Advertisement

Beti-cel gene therapy contains autologous CD34+ hematopoietic stem cells and progenitor cells transduced with the BB305 lentiviral vector encoding the β-globin (βA-T87Q) gene. Franco Locatelli and the team aimed to evaluate its safety and efficacy in adult and pediatric patients with transfusion-dependent β-thalassemia and a non–β0/β0 genotype.

For this purpose, 23 patients underwent myeloablation with busulfan (with doses adjusted on the basis of pharmacokinetic analysis) and received beti-cel intravenously. They were followed for a median of 29.5 months.

The primary endpoint was transfusion independence defined as weighted average hemoglobin level of ≥9 g per deciliter without red-cell transfusions for ≥12 months. 

The study revealed the following findings:

  • Transfusion independence occurred in 20 of 22 patients who could be evaluated (91%), including 6 of 7 patients (86%) who were younger than 12 years of age.
  • The average hemoglobin level during transfusion independence was 11.7 g per deciliter.
  • Twelve months after beti-cel infusion, the median level of gene therapy–derived adult hemoglobin (HbA) with a T87Q amino acid substitution (HbAT87Q) was 8.7 g per deciliter in patients who had transfusion independence.
  • The safety profile of beti-cel was consistent with that of busulfan-based myeloablation.
  • Four patients had at least one adverse event that was considered by the investigators to be related or possibly related to beti-cel; all events were nonserious except for thrombocytopenia (in 1 patient).
  • No cases of cancer were observed.

To conclude, treatment with beti-cel resulted in a sustained HbAT87Q level and a total hemoglobin level that was high enough to enable transfusion independence in most patients with a non–β0/β0 genotype, including those younger than 12 years of age.

Reference:

The study titled, "Betibeglogene Autotemcel Gene Therapy for Non–β0/β0 Genotype β-Thalassemia," was published in the New England Journal of Medicine.

DOI: https://www.nejm.org/doi/full/10.1056/NEJMoa2113206

Tags:    
Article Source : New England Journal of Medicine

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News